Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in MF patients



Presented at the 24th Congress of the European Hematology Association (EHA), Promedior, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 2 study of PRM-151 in myelofibrosis (MF) patients who were ineligible for Ruxolitinib or had failed the drug. Promedior looks forward to advancing the clinical program for PRM-151 in both MF and will explore other fibrotic indications in the future.

PRM-151 demonstrated promising antifibrotic activity as measured by reduction in bone marrow fibrosis and improvement in hematologic measures. According to Dr. Srdan Verstovsek, Professor, Leukemia Department, MD Anderson Cancer Center. "Patients also showed a reduction in their myeloproliferative neoplasm symptoms, as well as a trend to prolonged survival with PRM-151 monotherapy in these refractory MF patients with great unmet need." 

Click here to read the full release





Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.



Get free, timely information on living with an MPN.